| Allison Margery Goldsmith, | |
|
224 Circle Dr, Traverse City, MI 49684-2700 | |
| (231) 932-4855 | |
| (231) 935-0613 |
| Full Name | Allison Margery Goldsmith |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 224 Circle Dr, Traverse City, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023351731 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4301108633 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Munson Medical Center | Traverse city, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bay Area Family Care Of Traverse City Plc | 9830176650 | 4 |
News Archive
Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years - a finding that makes the White House happy.
› Verified 4 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years - a finding that makes the White House happy.
› Verified 4 days ago
| Entity Name | Bay Area Family Care Of Traverse City Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407858798 PECOS PAC ID: 9830176650 Enrollment ID: O20040630000532 |
News Archive
Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years - a finding that makes the White House happy.
› Verified 4 days ago
| Entity Name | Munson Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821398322 PECOS PAC ID: 8820277015 Enrollment ID: O20110120000061 |
News Archive
Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years - a finding that makes the White House happy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allison Margery Goldsmith, 224 Circle Drive, Traverse City, MI 49684 Ph: (231) 932-4855 | Allison Margery Goldsmith, 224 Circle Dr, Traverse City, MI 49684-2700 Ph: (231) 932-4855 |
News Archive
Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years - a finding that makes the White House happy.
› Verified 4 days ago
John P Milliken, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 224 Circle Dr, Traverse City, MI 49684 Phone: 231-935-0525 Fax: 231-935-0529 | |
Dr. David R Hendricks, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 153 1/2 E Front St, Traverse City, MI 49684 Phone: 231-941-6670 Fax: 231-941-6675 | |
Dr. Jill Elizabeth Vollbrecht, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5015 N Royal Dr, Traverse City, MI 49684 Phone: 231-935-0850 Fax: 231-935-0850 | |
Dr. Katrina Marie Lawrence-wolff, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 3537 W Front St Ste A, Traverse City, MI 49684 Phone: 231-935-8330 Fax: 231-935-3437 | |
Steven M. Lamie, M. D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3537 W Front St, Suite I, Traverse City, MI 49684 Phone: 231-935-8950 Fax: 231-935-8868 | |
Anne M Hepner, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 Sixth St, Suite 200, Traverse City, MI 49684 Phone: 231-935-5800 Fax: 231-935-5799 | |
Mark V Galan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 208, Traverse City, MI 49684 Phone: 231-935-5710 Fax: 231-935-9045 |